#558 INCREASED PROSTATE SMOOTH MUSCLE CONTRACTIONS AND REDUCED RELAXATIONS IN MIDDLE-AGED RATS.

#559 BAY 41-2272, a soluble guanylate cyclase stimulator, improves bladder function in partial bladder outlet obstructed mice

#560 Therapeutic effects of intravesical onabotulinumtoxinA injection on IC/BPS refractory to conventional treatment - a randomized, double blind, placebo controlled study

#561 Botulinum toxin A urethral sphincter injection for non-obstructive voiding dysfunction – A randomized, double-blind, placebo control, multicenter study

#562 Resveratrol improves systemic oxidative stress and lower urinary tract dysfunction in obese mice

#563 Patient initial treatment preference is anticholinergic therapy over onabotulinumtoxinA for urgency urinary incontinence regardless of symptom severity

#564 The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomized, double- blind, placebo-controlled phase 2 study

#565 The efficacy and safety of flexible dose imidafenacin (0.2mg or 0.4mg), for the treatment of overactive bladder and nocturia

#566 Mirabegron in treatment of neurological overactive bladder in multiple sclerosis patients

#567 Does bacterial vaccine become clinically significant in neurogenic bladder patients at clean intermittent catheterization?

#568 Characterization of muscarinic receptor binding of fesoterodine after oral administration in rats

#569 Intravesical instillation of Liposome encapsulated onabotulinumtoxinA for patients with overactive bladder – A pilot clinical study

#570 The effects of chronic nitric oxide synthesis inhibition on bladder function in partial outlet obstructed mice

#571 How long can antimuscarinic treatment be effective in treatment of overactive bladder – analysis of the predictive factors
Delegates Choice Award

#572 Predictors of urinary retention in patients undergoing open renal surgery with thoracic epidurally analgesia: A pooled analysis

#573 Oral administration of prosultiamine improved the symptoms in patients with overactive bladder associated with HTLV-1-related myelopathy/tropical spastic paraparesis, and also reduced urinary biomarkers.

#574 The effects of tolterodine and 5-hydroxymethyl tolterodine (5HMT) on carbachol-induced contraction in human bladder smooth muscles in normal state and in detrusor overactivity associated with benign prostatic hyperplasia

#575 Superior Efficacy of Combination Pharmacotherapy for Treatment of Neurogenic Detrusor Overactivity

#576 Persistence with mirabegron in patients with overactive bladder : A Comparative study of mirabegron and antimuscarinics.

#577 USEFULL OF INTRAVESICAL INSTILLATION OF HYALURONIC ACID AND CHONDROITIN SULPHATE IN PREVENTING RECURRENT BACTERIAL CYSTITIS

#578 A comparative study on the efficacy of solifenacin succinate in patients with urinary frequency with or without urgency

#579 Evaluating the Magnitude of Improvements in Patient-Reported Outcomes by Age in Overactive Bladder Patients: A Pooled Analysis of Two Mirabegron Clinical Trials

#580 100 UNITS OF INTRA-DETRUSOR ONABOTULINUMTOXIN A FOR IDIOPATIC OVERACTIVE BLADDER PATIENTS REFRACTORY TO ANTIMUSCARINIC THERAPY
Delegates Choice Award

#581 Combined intravesical trigonal and urethral injections of onabotulinumtoxinA in the treatment of patients with hypersensitive bladder and voiding dysfunction – a pilot study

#582 A Prospective, Multicenter, Observational Study to Estimate the Dry Mouth in Overactive Bladder Patients Treated with Solilfenacin

#583 BETA-3 RECEPTOR AGONIST, MIRABEGRON RELAXES ISOLATED PROSTATE FROM HUMAN AND RABBIT: NEW THERAPEUTIC INDICATION

#584 COMBINATION THERAPY WITH SOLIFENACIN 10 mg AND TAMSULOSIN 0,4 mg ORAL FOR URGENCY URINARY INCONTINENCE IN MEN. EFFICACY AND SAFETY RESULTS

#585 PROPIVERINE ER AND EFFECTS OF FLEXIBLE DOSING IN 1335 PATIENTS WITH OAB: RESULTS OF A NON-INTERVENTIONAL STUDY